コンテンツへスキップ
Merck
  • Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties.

Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties.

Experimental neurology (2014-12-03)
Mario A Saporta, Vu Dang, Dmitri Volfson, Bende Zou, Xinmin Simon Xie, Adijat Adebola, Ronald K Liem, Michael Shy, John T Dimos
要旨

Charcot-Marie-Tooth (CMT) disease is a group of inherited peripheral neuropathies associated with mutations or copy number variations in over 70 genes encoding proteins with fundamental roles in the development and function of Schwann cells and peripheral axons. Here, we used iPSC-derived cells to identify common pathophysiological mechanisms in axonal CMT. iPSC lines from patients with two distinct forms of axonal CMT (CMT2A and CMT2E) were differentiated into spinal cord motor neurons and used to study axonal structure and function and electrophysiological properties in vitro. iPSC-derived motor neurons exhibited gene and protein expression, ultrastructural and electrophysiological features of mature primary spinal cord motor neurons. Cytoskeletal abnormalities were found in neurons from a CMT2E (NEFL) patient and corroborated by a mouse model of the same NEFL point mutation. Abnormalities in mitochondrial trafficking were found in neurons derived from this patient, but were only mildly present in neurons from a CMT2A (MFN2) patient. Novel electrophysiological abnormalities, including reduced action potential threshold and abnormal channel current properties were observed in motor neurons derived from both of these patients. Human iPSC-derived motor neurons from axonal CMT patients replicated key pathophysiological features observed in other models of MFN2 and NEFL mutations, including abnormal cytoskeletal and mitochondrial dynamics. Electrophysiological abnormalities found in axonal CMT iPSC-derived human motor neurons suggest that these cells are hyperexcitable and have altered sodium and calcium channel kinetics. These findings may provide a new therapeutic target for this group of heterogeneous inherited neuropathies.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
レチノイン酸, ≥98% (HPLC), powder
Sigma-Aldrich
L-アスコルビン酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-アスコルビン酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-アスコルビン酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-アスコルビン酸, 99%
Sigma-Aldrich
L-アスコルビン酸, reagent grade, crystalline
Supelco
アスコルビン酸, Pharmaceutical Secondary Standard; Certified Reference Material
USP
アスコルビン酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L-アスコルビン酸, ACS reagent, ≥99%
Supelco
L-アスコルビン酸, analytical standard
Sigma-Aldrich
6-[4-(2-ピペリジン-1-イルエトキシ)フェニル]-3-ピリジン-4-イルピラゾロ[1,5-a]ピリミジン, ≥98% (HPLC)
Sigma-Aldrich
L-アスコルビン酸, meets USP testing specifications
Sigma-Aldrich
L-アスコルビン酸, reagent grade
Sigma-Aldrich
L-アスコルビン酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L-アスコルビン酸, FCC, FG
Sigma-Aldrich
L-アスコルビン酸, BioUltra, ≥99.5% (RT)
アスコルビン酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-アスコルビン酸, puriss. p.a., ≥99.0% (RT)
Supelco
L-アスコルビン酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-アスコルビン酸, tested according to Ph. Eur.
Supelco
4-tert-オクチルフェノールモノエトキシラート 溶液, 10 μg/mL in acetone, analytical standard